Geron, GE Healthcare Strike Stem-Cell Deal


Published On: July 1st, 2009

stem cellsBiotech company Geron will partner with GE Healthcare to develop products made from human embryonic stem cells that may help discover and develop new drugs, the companies said today.

The terms of the deal weren’t disclosed but Geron’s stock is up 17% in mid-day trading.

Geron got the nod from the FDA in January to conduct a small trial using stem cells to treat people with spinal-cord injuries. A number of large drug makers, like Pfizer, J&J, GlaxoSmithKline and Roche, have also expressed interest in developing stem-cell treatments. And in March, President Obama lifted the restrictions banning federal funding of research using embryonic stem cells, which can turn into any cells in the body.

Last month, GE unveiled its “Healthymagination” effort, that includes a $3 billion initiative to develop products to lower costs, increase access and improve health-care quality, noted the WSJ .

“This agreement marks a further step in GE Healthcare’s cell technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and therapy markets,” Konstantin Fiedler, general manager of cell technologies at GE Healthcare, said in a statement.

Image of spinal cord with damaged myelin via CDC


Read the original post:
Geron, GE Healthcare Strike Stem-Cell Deal

STOP PANIC ATTACKS - A Natural Technique To Stop Panic Attacks and Anxiety Fast!

Stop Panic Attacks
The technique I teach has been developed by me Joe Barry, a former sufferer of all too frequent panic attacks and GAD. I developed a completely natural approach to eliminating 100% of general anxiety and panic attacks. This may seem very hard to believe for someone who may have had this condition for some time but believe me the new information is now available to be free from anxiety. I will reveal the whole technique to you.

try-now

YouTube Video



Loading...


Did You Know Did you know:


Infant mortality rates offer a vivid portrait of disparities in health. Even at birth, children from racial and ethnic minorities suffer worse health outcomes, including a notably higher rate of death

Related Posts

  • A.M. Vitals: J&J and Synthes Agree to $21.3 Billion Deal
    It’s Deal Time: Johnson & Johnson is buying Synthes, which makes surgical devices used for orthopedic and traumatic injuries, for $21.3 billion in cash and stock, the WSJ reports . The boards of the companies support the merger, but some Synthes shareholders may think the company is worth closer to 165 Swiss francs ($189) per..
  • In Earnings Call, J&J Defends Tylenol, Talks Up Elan Deal
    Johnson & Johnson said this morning that its second quarter earnings fell 3.6% compared to the year-earlier period. ..
  • Boston Scientific, J&J Deal is Latest Sign of Stent Suit Detente
    After years of bitter legal fights, peace could be rearing its ugly head in the stent world. ..
  • Analysts Like J&J’s Deal for Cougar
    Johnson & Johnson said late yesterday that it’s buying Cougar Biotechnology for about $894 million, or $43 a share. That’s a 16% premium to where the stock closed yesterday ..
  • GM, Union Near Deal On Health-Care Funds
    GM and the United Auto Workers reached a tentative deal today that could help GM reduce its $20 billion worth of retiree health-care obligations. ..
  • GE CEO to Tout Health-Care Push
    Note: This post is updated from its initial form to reflect new information released by GE this morning. GE CEO Jeff Immelt (pictured) is scheduled to be in Washington this morning, talking up the company’s plan to spend $6 billion over six years in an effort to expand its health-care business ..
Leave a comment
Comments are closed.
« Contaminated Sample of Nestle Cookie Dough Found After Genetech Deal, Roche Says ‘So Long, PhRMA; Hello, BIO’ »